GFR-话题@MedSci

#GFR#

483篇内容 | 2539人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534500, encodeId=693a153450022, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), objectType=article, longId=193163, objectId=3f4219316311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4219316311, replyNumber=0, likeNumber=63, createdTime=2020-05-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4219316311, moduleTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4219316311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534499, encodeId=49dc153449981, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2020：波奇替尼治疗NSCLC的EGFR 20ins的II期研究, objectType=article, longId=193160, objectId=a05f193160ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a05f193160ff, replyNumber=0, likeNumber=65, createdTime=2020-05-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a05f193160ff, moduleTitle=AACR 2020：波奇替尼治疗NSCLC的EGFR 20ins的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a05f193160ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534498, encodeId=77c71534498bc, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, objectType=article, longId=193124, objectId=e57a19312429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57a19312429, replyNumber=0, likeNumber=55, createdTime=2020-04-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57a19312429, moduleTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57a19312429)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534497, encodeId=0738153449ed7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, objectType=article, longId=193108, objectId=28561931082d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28561931082d, replyNumber=0, likeNumber=86, createdTime=2020-04-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28561931082d, moduleTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28561931082d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534496, encodeId=93451534496af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, objectType=article, longId=193107, objectId=ee7719310e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7719310e83, replyNumber=0, likeNumber=73, createdTime=2020-04-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7719310e83, moduleTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee7719310e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534495, encodeId=6d4d153449562, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell Death Dis：正反馈通路SNAIL/miR590/VEGFR/NRP1促进胃癌发生发展, objectType=article, longId=192883, objectId=fd0a1928834e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd0a1928834e, replyNumber=0, likeNumber=60, createdTime=2020-04-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd0a1928834e, moduleTitle=Cell Death Dis：正反馈通路SNAIL/miR590/VEGFR/NRP1促进胃癌发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd0a1928834e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534494, encodeId=d4a31534494b2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性, objectType=article, longId=192882, objectId=1354192882ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1354192882ef, replyNumber=0, likeNumber=72, createdTime=2020-04-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1354192882ef, moduleTitle=Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1354192882ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534493, encodeId=0484153449355, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：一种评估EGFR影响的新型诊断系统可作为肺腺癌的预后和治疗指标, objectType=article, longId=192637, objectId=62f419263edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62f419263edc, replyNumber=0, likeNumber=0, createdTime=2020-04-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62f419263edc, moduleTitle=Sci Rep：一种评估EGFR影响的新型诊断系统可作为肺腺癌的预后和治疗指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62f419263edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534492, encodeId=0b72153449293, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, objectType=article, longId=192611, objectId=3a2319261150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a2319261150, replyNumber=0, likeNumber=58, createdTime=2020-04-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a2319261150, moduleTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a2319261150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, objectType=article, longId=192270, objectId=8c6d1922e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6d1922e0a7, replyNumber=0, likeNumber=64, createdTime=2020-04-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6d1922e0a7, moduleTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c6d1922e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534490, encodeId=51151534490cc, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效, objectType=article, longId=192016, objectId=e03e1920168c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e03e1920168c, replyNumber=0, likeNumber=49, createdTime=2020-04-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e03e1920168c, moduleTitle=III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e03e1920168c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534488, encodeId=6c47153448877, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, objectType=article, longId=191912, objectId=afff191912f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afff191912f3, replyNumber=0, likeNumber=82, createdTime=2020-04-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afff191912f3, moduleTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afff191912f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534487, encodeId=879c153448ee8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌, objectType=article, longId=191608, objectId=8be819160868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8be819160868, replyNumber=0, likeNumber=69, createdTime=2020-04-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8be819160868, moduleTitle=Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8be819160868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534489, encodeId=030b1534489c5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择, objectType=article, longId=191175, objectId=f0141911e5a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0141911e5a2, replyNumber=0, likeNumber=65, createdTime=2020-04-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0141911e5a2, moduleTitle=褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0141911e5a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534486, encodeId=316915344867e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=PDGFRα靶向新药avapritinib在中国台湾申请用于治疗晚期胃肠道间质瘤成人患者, objectType=article, longId=191054, objectId=22d01910546b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22d01910546b, replyNumber=0, likeNumber=62, createdTime=2020-03-31, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22d01910546b, moduleTitle=PDGFRα靶向新药avapritinib在中国台湾申请用于治疗晚期胃肠道间质瘤成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22d01910546b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534484, encodeId=edc7153448483, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, objectType=article, longId=190912, objectId=52ec19091290, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52ec19091290, replyNumber=0, likeNumber=66, createdTime=2020-03-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52ec19091290, moduleTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52ec19091290)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534485, encodeId=e3f61534485e3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, objectType=article, longId=190904, objectId=3990190904f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3990190904f4, replyNumber=0, likeNumber=58, createdTime=2020-03-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3990190904f4, moduleTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3990190904f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534483, encodeId=17a61534483f5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, objectType=article, longId=190514, objectId=8e2119051451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e2119051451, replyNumber=0, likeNumber=55, createdTime=2020-03-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e2119051451, moduleTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e2119051451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534482, encodeId=036c153448267, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell Death Dis：ZBTB20调节小鼠肝脏再生中的EGFR表达和肝细胞增殖, objectType=article, longId=190313, objectId=f74a190313ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f74a190313ed, replyNumber=0, likeNumber=54, createdTime=2020-03-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f74a190313ed, moduleTitle=Cell Death Dis：ZBTB20调节小鼠肝脏再生中的EGFR表达和肝细胞增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f74a190313ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534481, encodeId=4164153448110, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=0, createdTime=2020-03-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究)

2020-05-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2020：波奇替尼治疗NSCLC的EGFR 20ins的II期研究

2020-05-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定

2020-04-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布

2020-04-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2020：大样本NSCLC中的FGFR基因突变结果发布

2020-04-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell Death Dis：正反馈通路SNAIL/miR590/VEGFR/NRP1促进胃癌发生发展

2020-04-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性

2020-04-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：一种评估EGFR影响的新型诊断系统可作为肺腺癌的预后和治疗指标

2020-04-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

FDA批准胆管癌FGFR靶向药pemigatinib获批

2020-04-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理

2020-04-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效

2020-04-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准

2020-04-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌

2020-04-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择

2020-04-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

PDGFRα靶向新药avapritinib在中国台湾申请用于治疗晚期胃肠道间质瘤成人患者

2020-03-31

liuyiping (审核中...)

前往app查看评论内容

#GFR#

刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑

2020-03-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局

2020-03-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗

2020-03-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell Death Dis：ZBTB20调节小鼠肝脏再生中的EGFR表达和肝细胞增殖

2020-03-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-03-16

科室
- - 订阅+
  - 更多科室
工具
服务